Summit Therapeutics Inc. (NASDAQ:SMMT) Q3 2023 Results Conference Call November 7, 2023 9:00 AM ET
Company Participants
Dave Gancarz - Chief Business and Strategy Officer
Bob Duggan - Chairman of the Board and Chief Executive Officer
Dr. Maky Zanganeh - Chief Executive Officer and President
Ankur Dhingra - Chief Financial Officer
Dr. Allen Yang - Chief Medical Officer
Manmeet Soni - Chief Operating Officer
Conference Call Participants
Brad Canino - Stifel
Operator
Good morning, and welcome to the Summit Therapeutics Third Quarter 2023 Earnings and Update Call. All participants will be able to listen only until the question-and-answer portion of this call. We do not expect any technical difficulties today; however, in the event that we lose the webcast connection and we are unable to provide any updates, please wait up to 10 minutes for resolution. Please refer to the Company's website for updates. Please note that today's call is being recorded. [Operator Instructions]
At this time, I would like to introduce the call to Dave Gancarz, Chief Business and Strategy Officer. You may proceed.
Dave Gancarz
Thank you for joining us. Our press release was issued earlier this morning and is available on the homepage of our website. Our Form 10-Q was also filed earlier this morning and is available on our website. Today's call is being simultaneously webcast and an archived replay will be available later today on our website, www.smmttx.com.
Joining me on the call today is Bob Duggan, our Chairman of the Board and Chief Executive Officer; Dr. Maky Zanganeh, our Chief Executive Officer and President; Ankur Dhingra, our Chief Financial Officer; Dr. Allen Yang, our Chief Medical Officer.
And in addition, we are joined by a new Chief Operating Officer, Manmeet Soni. Manmeet joins us from Reata Pharmaceuticals, where he was the President, Chief Operating Officer and Chief Financial Officer. Reata was recently purchased by Biogen for approximately $7.5 billion. Manmeet was previously the CFO at Alnylam Pharmaceuticals and ARIAD Pharmaceuticals. Before that, he was the CFO of Pharmacyclics. Manmeet will continue to serve on our Board, and he also serves on the Board of Pulse Biosciences. Manmeet will be responsible for all commercial activities, finance, clinical operations, manufacturing, legal, information technology, and human resources. In conjunction with Manmeet joining us, he invested $5 million in the Company in a private placement at market rates.
We are excited to have Manmeet join Team Summit, and I'd like to welcome Manmeet to the team.